KROS · Company research
Keros Therapeutics, Inc. Common Stock (KROS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Keros Therapeutics (KROS) Climbs 3.84% to $11.64 as Shares Push Toward Range Resistance - Dynamic Hedging - https://www.siam.in/ | Keros Therapeutics (KROS) Climbs 3.84% to $11.64 as Shares Push Toward Range Resistance - Dynamic Hedging https://www.siam.in/ | View source ↗ | https://www.siam.in/ | Oct 8, 2026 | neutral | 0 | 0.6 |
| Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward? | Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages - MarketBeat | Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50 According to Brokerages MarketBeat | View source ↗ | MarketBeat | Sep 29, 2026 | neutral | 0 | 0.6 |
| The first patient has received a drug being tested for Duchenne muscular dystrophy. Initial data are expected in 2027. - Stock Titan | The first patient has received a drug being tested for Duchenne muscular dystrophy. Initial data are expected in 2027. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Keros Therapeutics (NasdaqGM:KROS) Stock Price - Simply Wall Street | Keros Therapeutics (NasdaqGM:KROS) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Sep 21, 2026 | neutral | 0 | 0.6 |
| Keros Therapeutics, Inc. SEC Filing (Sep 17, 2026) - Stock Titan | Keros Therapeutics, Inc. SEC Filing (Sep 17, 2026) Stock Titan | View source ↗ | Stock Titan | Sep 17, 2026 | neutral | 0 | 0.6 |
| Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance | Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 2, 2026 | neutral | 0 | 0.6 |
| Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? - Yahoo Finance | Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 24, 2026 | neutral | 0 | 0.6 |
| Keros Therapeutics posts $28.7 million second quarter net loss | KROS Stock News - Quiver Quantitative | Keros Therapeutics posts $28.7 million second quarter net loss | KROS Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 3, 2026 | neutral | 0 | 0.6 |
| Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher - Simply Wall Street | Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher Simply Wall Street | View source ↗ | Simply Wall Street | Jul 17, 2026 | neutral | 0 | 0.6 |
| KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - Yahoo Finance | KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 Yahoo Finance | View source ↗ | Yahoo Finance | May 22, 2026 | neutral | 0 | 0.6 |
| Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - Yahoo Finance | Should You Buy KROS After Q1 Miss and Takeda Deal Reset? Yahoo Finance | View source ↗ | Yahoo Finance | May 22, 2026 | neutral | 0 | 0.6 |
| Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance | Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 Yahoo Finance | View source ↗ | Yahoo Finance | May 17, 2026 | neutral | 0 | 0.6 |
| Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives - Simply Wall Street | Keros Therapeutics (KROS) Revenue Collapse To US$0.4 Million Challenges Bullish Growth Narratives Simply Wall Street | View source ↗ | Simply Wall Street | May 14, 2026 | neutral | 0 | 0.6 |
| KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - TradingView | KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? TradingView | View source ↗ | TradingView | Apr 20, 2026 | neutral | 0 | 0.6 |
| Keros Therapeutics (KROS) Stock Forecast and Price Target 2026 $KROS - MarketBeat | Keros Therapeutics (KROS) Stock Forecast and Price Target 2026 $KROS MarketBeat | View source ↗ | MarketBeat | May 11, 2024 | neutral | 0 | 0.6 |
| Keros Therapeutics (KROS) - Zacks Investment Research | Keros Therapeutics (KROS) Zacks Investment Research | View source ↗ | Zacks Investment Research | Apr 15, 2020 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.